These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 29468908

  • 1. Inflammatory bowel disease and anemia: intravenous iron treatment.
    Kangaspunta M, Haapamäki J, Färkkilä M, Arkkila P.
    Scand J Gastroenterol; 2018 Apr; 53(4):430-434. PubMed ID: 29468908
    [Abstract] [Full Text] [Related]

  • 2. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F, Löhr B, Laubender RP, Tillack C, Schnitzler F, Breiteneicher S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S.
    Digestion; 2012 Apr; 85(1):47-54. PubMed ID: 22179489
    [Abstract] [Full Text] [Related]

  • 3. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S, Maltez C, Lopes AI.
    Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L, Pensabene L, El-Khouly S, Chadokufa S, McCartney S, Saliakellis E, Kiparissi F, Borrelli O.
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [Abstract] [Full Text] [Related]

  • 6. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C.
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [Abstract] [Full Text] [Related]

  • 7. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW, Cançado RD, Sobrado LF, Frugis MO, Sobrado MF.
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X, Borrás-Blasco J, Molés JR, Boscá M, Cortés E.
    PLoS One; 2015 Dec; 10(5):e0128156. PubMed ID: 26011514
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U.
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of parenteral iron in children with inflammatory bowel disease.
    Papadopoulos M, Patel D, Korologou-Linden R, Goto E, Soondrum K, Fell JME, Epstein J.
    Br J Clin Pharmacol; 2018 Apr; 84(4):694-699. PubMed ID: 29266387
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.
    Laass MW, Straub S, Chainey S, Virgin G, Cushway T.
    BMC Gastroenterol; 2014 Oct 17; 14():184. PubMed ID: 25326048
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
    Gilmartin CE, Hoang T, Cutts BA, Leung L.
    Int J Gynaecol Obstet; 2018 Jun 17; 141(3):315-320. PubMed ID: 29498039
    [Abstract] [Full Text] [Related]

  • 20. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
    Khoury A, Pagan KA, Farland MZ.
    Ann Pharmacother; 2021 Feb 17; 55(2):222-229. PubMed ID: 32633548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.